# Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women

> **NCT03060785** · PHASE1 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 16 (actual)

## Conditions studied

- HIV Prevention

## Interventions

- **DRUG:** Tenofovir Disoproxil Fumarate/Emtricitabine

## Key facts

- **NCT ID:** NCT03060785
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-08
- **Primary completion:** 2018-05-31
- **Final completion:** 2018-05-31
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03060785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03060785, "Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03060785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*